在p53KO胸腺淋巴瘤中准sphingosine激酶1的向
Fabiola N Velazquez1,2, Jeffrey L Stith1,2, Leiqing Zhang1,2
1Department of Medicine, Stony Brook University, Stony Brook, New York, USA.
概括
向松素激酶1 (SK1) 抑制了p53缺乏的小鼠中的淋巴瘤生长. 这种方法增加了细胞死亡和斯芬戈辛水平,为缺乏p53功能的瘤提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 生物化学 生化学
- 分子生物学分子生物学
背景情况:
- 斯芬哥辛激酶1 (SK1) 在包括淋巴瘤在内的各种癌症中被上调.
- 瘤蛋白P53 (p53) 突变或缺失与淋巴瘤预后不佳有关.
- SK1是潜在的治疗标,但其在p53被删除的癌症中的作用尚未被探索.
研究的目的:
- 评估在缺乏p53功能的淋巴瘤中准SK1的治疗潜力.
- 研究SK1抑制对p53缺陷淋巴瘤模型中的瘤生长和细胞死亡的影响.
主要方法:
- 在Trp53KO小鼠中利用了基因 (诱导式删除Sphk1) 和SK1的药理抑制.
- 在已建立的p53KO胸腺淋巴瘤模型中评估瘤生长,细胞死亡和脂水平.
主要成果:
- 准SK1显著降低了已确定的p53KO胸腺淋巴瘤的瘤生长.
- 抑制SK1导致瘤细胞死亡的增加.
- 对SK1的药理或遗传抑制导致了选择性黄素积累.
结论:
- 在没有p53.3的情况下,SK1在淋巴瘤的生长和维持中发挥着关键作用.
- SK1是治疗具有p53缺失或突变的淋巴瘤的有前途的治疗标.
- 准SK1代表了改善p53缺乏瘤的潜在策略.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K